Produits et services

Pharmaceuticals for genetic diseases and diseases associated to altered gene expression; biotechnology-formed genes for use in the manufacture of pharmaceuticals and therapeutics. Research in the field of gene editing technology and epigenetics; research and development in the pharmaceutical and biotechnology fields; biotechnology research. Medical services; medical diagnostic services; medical services in the field of personalized medicine.

Abrégé

The present invention relates to a microfluidic device configured to study epithelial and/or endothelial barrier functions in a human 3D cellular microtissue model, while also allowing the application of mechanical stimuli, such as a luminal and/or lateral flow. Embodiments comprise a tri-culture of human umbilical vein endothelial cells (HUVECs), human placental fibroblasts (HPF), and human placental pericytes (HPP) representative of a maternal-fetal interface (placental barrier), as well as a mammary duct interface, that is comprised of human primary mammary-derived endothelial cells, fibroblasts and inclusion of an epithelial layer (MCF10). The model can be extended to include tumors (cell line derived or patient-derived). The present invention further relates to a method for producing the human 3D vascular microtissue model using the microfluidic device according to the invention, as well as uses of the human 3D vascular microtissue models, for example to study cellular barrier function (permeability to solutes), the effects of interstitial, luminal and/or lateral flow and to study epithelial and/or endothelial barrier function (permeability to solutes), and extravascular matrix properties (diffusivity, stiffness, transport of molecules, antibodies and/or cells, and matrix proteins). The present invention further relates methods for representing a pre-eclamptic (disease) model of the placental barrier, and means for testing drug treatments.

Classes IPC  ?

• C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
• C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
• C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains

Abrégé

Disclosed herein is a method of operating a microfluidic system, a microfluidic system for manipulating sample objects, and a control system for operating a microfluidic system. The method according to the invention is for operating a microfluidic system that comprises a manipulation zone for manipulating sample objects flowing through the manipulation zone, a first detection zone arranged upstream of or in the manipulation zone and a second detection zone arranged upstream of, in or downstream of the manipulation zone. A first count is determined that characterizes a number of sample objects flowing through the first detection zone. Sample objects are manipulated in the manipulation zone. A second count is determined that characterizes a number of sample objects flowing through the second detection zone. One or more manipulation parameters for manipulating the sample objects in the manipulation zone are adjusted based on the first count and the second count.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes

Produits et services

Chemicals used in industry, science, agriculture, horticulture and forestry; fertilizers; defoliants; chemical substances for preserving foodstuffs; substances for preserving seeds; plant growth regulators; diagnostic preparations for scientific use for industrial purposes and for agriculture, other than for medical or veterinary purposes. Pesticides; insecticides; fungicides; herbicides; nematicides; rodenticides; insect growth regulators; preparations for activating the biological resistance of plants and seeds against insects, bacteria, fungal diseases, parasites, and weeds. Apparatus and instruments for scientific research in laboratories; data processing equipment; computer software. Agricultural, horticultural and forestry products and grains, not included in other classes; seeds, plants, young plants and other plants or seeds for propagating; live animals; fresh fruits and vegetables; seeds; natural plants and flowers; foodstuffs for animals; malt. Advertising; business management; business administration; office functions; all services relating to agriculture, horticulture, forestry, viticulture, arboriculture, gardening, market gardening, seed planting, seed manufacturing and protection. Consultancy in the field of scientific and industrial research; computer programming; computer software programming services; conducting scientific studies and analyses; scientific and industrial research; all services in the field of agriculture, horticulture, forestry, viniculture, seed planting, and animal nutrition. Agriculture, horticulture and forestry services.

Abrégé

A method for diagnosing pancreatic cancer in a subject comprising determining the abundance of several Microbiome species in a faecal sample from the said subject, and identifying the subject as having pancreatic cancer when the profile of abundance for the analysed species corresponds to a profile of abundance of the analysed species of a pancreatic cancer reference group, or not having pancreatic cancer when the profile of abundance for the analysed species corresponds to a profile of abundance of the analysed species of a reference group not having pancreatic cancer, as well as to a kit and its use for the diagnosis of pancreatic cancer.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries

Abrégé

This disclosure describes a method to measure RNA and gDNA simultaneously within the same cell in a targeted fashion with high coverage in all cells. This is achieved by combining in-situ reverse transcription (RT) with multiplexed PCR within droplets.

Produits et services

(1) Chemicals used in industry, science, agriculture, horticulture and forestry; fertilizers; defoliants; chemical substances for preserving foodstuffs; substances for preserving seeds; plant growth regulators; diagnostic preparations for scientific use for industrial purposes and for agriculture, other than for medical or veterinary purposes. (2) Pesticides; insecticides; fungicides; herbicides; nematicides; rodenticides; insect growth regulators; preparations for activating the biological resistance of plants and seeds against insects, bacteria, fungal diseases, parasites, and weeds. (3) Apparatus and instruments for scientific research in laboratories; data processing equipment; computer software. (4) Agricultural, horticultural and forestry products and grains, not included in other classes; seeds, plants, young plants and other plants or seeds for propagating; live animals; fresh fruits and vegetables; seeds; natural plants and flowers; foodstuffs for animals; malt. (1) Advertising; business management; business administration; office functions; all services relating to agriculture, horticulture, forestry, viticulture, arboriculture, gardening, market gardening, seed planting, seed manufacturing and protection. (2) Consultancy in the field of scientific and industrial research; computer programming; computer software programming services; conducting scientific studies and analyses; scientific and industrial research; all services in the field of agriculture, horticulture, forestry, viniculture, seed planting, and animal nutrition. (3) Agriculture, horticulture and forestry services.

Abrégé

The present invention relates to agents that increase the amount of a protein comprising a mutated RS domain amino acid sequence in the nucleus of a cell and/or decreases the amount of the same protein in the cytoplasm of said cell, for use in the prevention or treatment of a disease or condition that is related to the cytoplasmic mislocalization and/or the formation of granules and/or an aberrant splicing activity of the protein comprising the mutated RS domain amino acid sequence. In particular, the protein comprising a mutated RS domain amino acid sequence is RBM20 or an ortholog thereof, and/or the nuclear transporter protein is transportin 3 (TNPO3) or an ortholog thereof. Preferably, the disease or condition is myopathy, in particular dilated cardiomyopathy (DCM). The present invention further relates to a method for identifying suitable agents used to increase the amount of a protein comprising a mutated RS domain amino acid sequence in the nucleus of a cell and/or to decrease the amount of the same protein in the cytoplasm of said cell.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique

Abrégé

A sample mount (10) for imaging of at least one sample (50) comprises a hydrogel body (25) and at least one cavity (30). The cavity (30) is arranged in the hydrogel body (25) for holding the at least one sample (50) in a culturing environment (60). The at least one cavity (30) has an opening (25b) providing access to the least one cavity (30) for arranging the at least one sample (50) in the at least one cavity (25) and providing the at least one sample (50) with a culture medium and/or a gas.

Classes IPC  ?

• G01N 21/03 - Dispositions ou appareils pour faciliter la recherche optique - Détails de structure des cuvettes
• G01N 21/41 - Réfringence; Propriétés liées à la phase, p.ex. longueur du chemin optique
• G01N 21/64 - Fluorescence; Phosphorescence
• G01N 21/51 - Dispersion, c. à d. réflexion diffuse dans un corps ou dans un fluide à l'intérieur d'un récipient, p.ex. dans une ampoule

Abrégé

The present invention relates to improved transposase polypeptides having increased solubility. The enzyme of the invention was developed based on the Sleeping Beauty (SB) transposase. The invention provides further nucleic acids, vectors and recombinant cells encoding or containing the improved transposase, as well as a transposase system. Furthermore provided are medical and non-medical uses of the transposase of the invention for gene delivery. The invention is in particular useful as a tool for gene delivery in genetically modified cell based therapeutic approaches for treating various diseases.

Classes IPC  ?

• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p.ex. kinases (2.7)

Abrégé

The invention provides a method for quantifying the number of target entities that were successfully encapsulated into a microfluidic compartment such as a microfluidic droplet. The invention is predicated upon a continuous quantifiable detectable signal corresponding to the quantity of entities encapsulated in a microfluidic compartment. The present invention is useful in the context of high throughput microfluidic screening approaches which require thorough signal normalization in order to reliably improve signal to noise ratio and to reliably identify screening hits.

Classes IPC  ?

• G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes

Abrégé

A method for determining spatial location of one or more biological components (12) in a biological sample (10) is proposed. The method comprises optically encoding (S100) the biological components (12) in the biological sample (10) with a plurality of fluorophores (31, 32, 33, 34) to create a combination of active fluorophore concentrations indicative of the spatial location of the one or more biological components (12); dissociating (S200) the biological components (12) from the biological sample (10) to create dissociated biological components (12) of the biological components (12); and - optically decoding (S300) by measuring the fluorescence (S310) of the dissociated biological components (12) and mapping (S320) to the spatial location of the biological components (12) in the non-dissociated sample (10).

Classes IPC  ?

• G01N 15/14 - Recherche par des moyens électro-optiques
• G06T 7/73 - Détermination de la position ou de l'orientation des objets ou des caméras utilisant des procédés basés sur les caractéristiques
• G01N 15/10 - Recherche de particules individuelles
• G01N 15/1429 - Traitement du signal
• G01N 15/1434 - Dispositions optiques
• G01N 15/1433 - utilisant la reconnaissance d’image

Abrégé

The invention regards a method for screening for interactions between two compounds provided in libraries. The invention in particular provides a method for screening interactions, such as a binding between two molecules or macromolecules, that is not limited to a classical screening by bait and prey setup, and therefore allows for a high-complexity screening of large candidate libraries, including screening for immunological interactions such as interactions between T-cells and antigen presenting cells, or B-cells and their antigenic targets.

Classes IPC  ?

• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN

Abrégé

The present invention relates to the novel compounds of general formula (I) as defined below. The invention further relates to a pharmaceutical composition comprising said compound of formula (I). The invention further relates to said compound of general formula (I) as defined below for use as medicament in the treatment of an autotaxin (ATX) related disease.

Classes IPC  ?

• C07D 405/10 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
• A61K 31/404 - Indoles, p.ex. pindolol
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and/or treatment of bacterial infections and antibacterial-induced dysfunctions. The compositions of the present invention demonstrate high species-specificity in inhibiting the growth of a small number of bacterial species, and most importantly are effective also against multi drug resistant (MDR) clinical isolate species. Interestingly, one of those combinations pairs a non-antibiotic drug, vanillin, with an antibiotic drug, spectinomycin, to demonstrate a surprisingly strong inhibitory effect on the growth of clinically relevant Gram-negative pathogenic and multi-drug resistant E. coli isolates. A second set of compounds combines the polymyxin colistin with loperamide, a rifamycin, or a macrolide. Importantly, this invention relates to combinations that enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development efforts in order to prevent major side effects of antibacterial strategies. This invention also relates to pharmaceutical combinations useful to prevent an adverse effect on the gut microbiome, induced by the use of antibacterial compounds.

Classes IPC  ?

• C12Q 1/18 - Test de l'activité antimicrobienne d'un matériau
• A61K 31/11 - Aldéhydes
• A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
• A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p.ex. éthers en couronne, guanadrel
• A61K 31/445 - Pipéridines non condensées, p.ex. pipérocaïne
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
• A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p.ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
• A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides  contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
• A61K 38/12 - Peptides cycliques
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61P 31/04 - Agents antibactériens

Produits et services

Pharmaceuticals for genetic diseases and diseases associated to altered gene expression; biotechnology-formed genes for use in the manufacture of pharmaceuticals and therapeutics. Research in the field of gene editing technology and epigenetics; research and development in the pharmaceutical and biotechnology fields; biotechnology research. Medical services; medical diagnostic services; medical services in the field of personalized medicine.

Abrégé

in vivoin vivo infection outcome of clinically relevant Gram-positive pathogens, such as MRSA. Importantly, this invention relates to combinations that target multi-drug resistant strains, constituting a major effort of antimicrobial therapy development in the current antimicrobial resistance crisis.

Classes IPC  ?

• A61K 38/14 - Peptides contenant des radicaux saccharide; Leurs dérivés
• A61K 31/505 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime
• A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p.ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61P 31/04 - Agents antibactériens

Abrégé

Provided herein are compositions and methods for treating or preventing dilated cardiomyopathy (DCM) in a subject in need thereof, e.g., through correcting one or more point mutations at the RBM20 locus using CRISPR-associated base editing.

Classes IPC  ?

• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
• C12N 15/864 - Vecteurs parvoviraux

Produits et services

Chemicals used in industry, science, agriculture, horticulture and forestry; fertilizers; defoliants; chemical substances for preserving foodstuffs; substances for preserving seeds; plant growth regulators; diagnostic preparations for scientific use for industrial purposes and for agriculture, other than for medical or veterinary purposes. Pesticides; insecticides; fungicides; herbicides; nematicides; rodenticides; insect growth regulators; preparations for activating the biological resistance of plants and seeds against insects, bacteria, fungal diseases, parasites, and weeds. Apparatus and instruments for scientific research in laboratories; data processing equipment; computer software. Agricultural, horticultural and forestry products and grains, not included in other classes; seeds, plants, young plants and other plants or seeds for propagating; live animals; fresh fruits and vegetables; seeds; natural plants and flowers; foodstuffs for animals; malt. Advertising; business management; business administration; office functions; all services relating to agriculture, horticulture, forestry, viticulture, arboriculture, gardening, market gardening, seed planting, seed manufacturing and protection. Scientific consultation services; computer programming; computer software programming services; conducting scientific studies and analyses; scientific and industrial research; all services in the field of agriculture, horticulture, forestry, viniculture, seed planting, and animal nutrition. Agriculture, horticulture and forestry services.

Abrégé

Described herein is a CRISPR guide and retron donor expressed separately to mediate genome editing by homology-directed repair. The split system works more efficiently than previous approaches employing retron-gRNA fusions, demonstrating that recruitment of the retron to the target site by Cas9 is not essential for retron-based editing and that retron and guide functionality can be enhanced when expressed via distinct promoters and RNA processing elements. More efficient editing was achieved with a mutant Cas9 nickase than with the fully active Cas9 nuclease in mammalian cells, avoiding the toxicity and error-prone repair pathways triggered by double-strand breaks which are of major concern for therapeutic applications.

Classes IPC  ?

• C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
• C12N 9/22 - Ribonucléases
• C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées

Abrégé

The present invention relates to a complex comprising i) a catalytically inactive site-specific nuclease linked to ii) an array of between two and ten, preferably three to seven effector domains each having a specific chromatin modifying activity, such as, for example, a specific DNA methylation activity, a histone methylation activity, a specific histone acetylation or ubiquitination activity, and/or a specific chromatin demethylation/deacetylation activity, wherein the effector domains are each separated by a linker providing sufficient distance between the domains and the nuclease in order not to substantially interfere with their specific chromatin modifying activities, and the binding of the site-specific nuclease, as well as respective methods involving the complex and use of the complex.

Classes IPC  ?

• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• C12N 9/10 - Transférases (2.)
• C12N 9/22 - Ribonucléases
• C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens

Abrégé

The present invention pertains to a method for identifying and/or characterizing a compound suitable for the prevention and/or treatment of a disease. The invention is based on the finding that the glycolytic enzyme Enolase 1 (ENO1) binds RNA, and its enzymatic activity is thereby regulated. The invention is further based on the finding that riboregulation of ENO1 affects cell differentiation, which plays a pivotal role in cancer. Accordingly, the invention provides a screening method for novel therapeutic compounds based on the binding of RNA to ENO1. Compounds screened according to the present invention can affect the binding of RNA to ENO1, which harbors the therapeutic potential for the treatment of diseases, in particular proliferative diseases, such as cancer. Methods of treatment using these compounds, as well as pharmaceutical compositions thereof, are also provided.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
• C12Q 1/527 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une lyase
• C12N 9/88 - Lyases (4.)

Abrégé

The present invention pertains to a new method for the prognosis, diagnosis, stratification and/or monitoring of a therapy of a disorder in a subject. The method is based on the determination of the level of at least one first biomarker indicative and/or selective for the status and/or activity of the pathway regulating N6-methyladenosine (m6A) mRNA modification, and the determination of the level, mutation status, and/or activity of at least one second biomarker indicative and/or selective for the status and/or activity of the pathway regulating 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U)-tRNA modification as combined biomarkers. The new biomarkers of the invention allow diagnosing and even stratifying of a disorder in a patient, estimating a patient's prognosis, and monitoring therapy success of patients, in particular of cancer patients, such as breast cancer patients. Further provided are kits for the prognosis, diagnosis, and/or monitoring of a disease, condition or disorder in a subject. The invention also pertains to a compound for use in the treatment of a disease, condition or disorder, wherein the compound specifically reduces or enhances the level, mutation status, and/or activity of a gene, mRNA or protein regulating m6A mRNA modification in a cell, and/or a gene, mRNA or protein regulating mcm5s2U-tRNA modification in a cell.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

This invention relates to novel surface modified viral capsids and recombinant virions comprising the same. Furthermore, this invention concerns intermediates for the preparation of surface modified viral capsids. The surface modified viral capsids are designed to selectively and/or more efficiently deliver gene therapy. The surface modified viral capsids, when incorporated into a recombinant virion, can be used to treat an illness that is characterized by genetic abnormality.

Classes IPC  ?

• A61K 35/76 - Virus; Particules sous-virales; Bactériophages
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• C12N 15/86 - Vecteurs viraux
• A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
• A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
• C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus

Abrégé

A computer implemented method for designing at least one protein comprises creating at least one amino acid sequence to be tested, wherein ones of the amino acids, contained in the amino acid sequence to be tested, are selected according to a probability distribution; predicting, from the aligned at least one amino acid sequence, structural properties of the at least one protein; calculating, based on the structural properties of the at least one protein, a value of a fitness function for the at least one amino acid sequence to be tested; selecting or deselecting, dependent on the value of the fitness function, the at least one amino acid sequence to be tested. The amino acid sequence may be post-processed to be more native-like, have enhanced solubility, and/or improved expression.

Classes IPC  ?

• G16B 15/20 - Repliement de protéines ou de domaines
• G16B 15/30 - Ciblage de médicament à l’aide de données structurelles; Prévision d’amarrage ou de liaison moléculaire
• G16B 40/20 - Analyse de données supervisée

Abrégé

A method for storage of an item of information (210) is disclosed. The method comprises encoding bytes (720) in the item of information (210), and representing using a schema the encoded bytes by a DNA nucleotide to produce a DNA sequence (230). The DNA sequence (230) is broken into a plurality of overlapping DNA segments (240) and indexing information (250) added to the plurality of DNA segments. Finally, the plurality of DNA segments (240) is synthesized (790) and stored (795).

Classes IPC  ?

• G06F 12/02 - Adressage ou affectation; Réadressage
• G16B 50/40 - Cryptage de données génétiques
• G16B 50/50 - Compression de données génétiques
• G16B 30/00 - TIC spécialement adaptées à l’analyse de séquences impliquant des nucléotides ou des aminoacides
• B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
• G06N 3/12 - Agencements informatiques fondés sur des modèles biologiques utilisant des modèles génétiques

Abrégé

The present invention relates to the field of microfluidics and in particular to devices and methods for sorting objects in microfluidic channels. These devices and methods allow for fast and robust sorting in two-way and multi-way setups. They also enable sorting over extended periods of time.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
• B03C 5/02 - Séparateurs
• G01N 15/00 - Recherche de caractéristiques de particules; Recherche de la perméabilité, du volume des pores ou de l'aire superficielle effective de matériaux poreux
• G01N 15/10 - Recherche de particules individuelles
• G01N 15/149 - spécialement adaptées au tri des particules, p.ex. selon leur taille ou leurs propriétés

Abrégé

A method for storage of an item of information (210) is disclosed. The method comprises encoding bytes (720) in the item of information (210), and representing using a schema the encoded bytes by a DNA nucleotide to produce a DNA sequence (230). The DNA sequence (230) is broken into a plurality of overlapping DNA segments (240) and indexing information (250) added to the plurality of DNA segments. Finally, the plurality of DNA segments (240) is synthesized (790) and stored (795).

Classes IPC  ?

• G06F 12/02 - Adressage ou affectation; Réadressage
• G16B 50/40 - Cryptage de données génétiques
• G16B 50/50 - Compression de données génétiques
• G16B 30/00 - TIC spécialement adaptées à l’analyse de séquences impliquant des nucléotides ou des aminoacides
• B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
• G06N 3/123 - Informatique à ADN
• G11C 13/02 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage non couverts par les groupes , ou utilisant des éléments dont le fonctionnement dépend d'un changement chimique

Abrégé

The invention relates to archaeal pyrrolysyl tRNA synthetases lacking a nuclear localization signal and/or comprising a nuclear export signal. The invention also relates to polynucleotides encoding said pyrrolysyl tRNA synthetases, eukaryotic cells comprising said polynucleotide and tRNA acylated by the pyrrolysyl tRNA synthetase or a polynucleotide encoding such tRNA, methods utilizing said cells for preparing polypeptides comprising unnatural amino acid residues, and kits useful in said methods.

Classes IPC  ?

• C12N 9/00 - Enzymes, p.ex. ligases (6.); Proenzymes; Compositions les contenant; Procédés pour préparer, activer, inhiber, séparer ou purifier des enzymes
• C12P 21/00 - Préparation de peptides ou de protéines

Abrégé

A method for storage of an item of information (210) is disclosed. The method comprises encoding bytes (720) in the item of information (210), and representing using a schema the encoded bytes by a DNA nucleotide to produce a DNA sequence (230). The DNA sequence (230) is broken into a plurality of overlapping DNA segments (240) and indexing information (250) added to the plurality of DNA segments. Finally, the plurality of DNA segments (240) is synthesized (790) and stored (795).

Classes IPC  ?

• G06F 12/02 - Adressage ou affectation; Réadressage
• B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
• G06N 3/12 - Agencements informatiques fondés sur des modèles biologiques utilisant des modèles génétiques
• G16B 50/40 - Cryptage de données génétiques
• G16B 50/50 - Compression de données génétiques
• G16B 30/00 - TIC spécialement adaptées à l’analyse de séquences impliquant des nucléotides ou des aminoacides

Abrégé

The present invention relates to improved transposase polypeptides having increased solubility. The enzyme of the invention was developed based on the Sleeping Beauty (SB) transposase. The invention provides further nucleic acids, vectors and recombinant cells encoding or containing the improved transposase, as well as a transposase system. Furthermore provided are medical and non-medical uses of the transposase of the invention for gene delivery. The invention is in particular useful as a tool for gene delivery in genetically modified cell based therapeutic approaches for treating various diseases.

Classes IPC  ?

• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p.ex. kinases (2.7)

Abrégé

The invention pertains to means and methods for the detection of telomere fusion events, and the use of such means and methods in the detection and diagnosis of a disease associated with telomere fusion events, such as a cancer disease.

Classes IPC  ?

• C12Q 1/686 - Réaction en chaine par polymérase [PCR]
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The invention pertains to means and methods for the detection of telomere fusion events, and the use of such means and methods in the detection and diagnosis of a disease associated with telomere fusion events, such as a cancer disease.

Classes IPC  ?

• C12Q 1/686 - Réaction en chaine par polymérase [PCR]
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention relates to a yeast cell producing at least one secreted protein of interest, wherein said cell comprises at least one additional fungal gene showing increased expression and/or overexpression, showing reduced expression and/or inactivation, wherein said gene improves the production of the at least one secreted protein of interest. The present invention further relates to respective methods for production and uses of the yeast cell.

Classes IPC  ?

• C07K 14/37 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de champignons
• C07K 14/39 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de champignons provenant de levures
• C12N 9/90 - Isomérases (5.)
• C12N 15/80 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons
• C12P 21/00 - Préparation de peptides ou de protéines

Abrégé

The invention relates to the field of bioconjugation of functional entities (payloads) to targeting agents, in particular biological targeting agents, such as antibody drug conjugates (ADCs), where one or more payload molecules are conjugated to a targeting agent, as for example a monoclonal antibody. More particularly, the present invention relates to novel hydrophilic tetrazine molecules and their preparation, which tetrazines allow a more efficient conjugation of payload molecules to targeting agents, like monoclonal antibodies. The present invention also relates to particular tetrazine intermediates useful for the preparation of correspondingly functionalized payload molecules. The present invention also relates to respective conjugates, in particular bio-conjugates and methods of their preparation. The invention also relates to the use of such conjugates of the present invention for use in medicine, to corresponding pharmaceutical compositions as well as to corresponding diagnostic and analytical kits.

Classes IPC  ?

• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
• C07D 257/08 - Cycles à six chaînons
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 498/14 - Systèmes condensés en ortho
• C07F 9/6524 - Composés hétérocycliques, p.ex. contenant du phosphore comme hétéro-atome du cycle comportant au moins quatre atomes d'azote comme uniques hétéro-atomes du cycle
• C07F 9/6558 - Composés hétérocycliques, p.ex. contenant du phosphore comme hétéro-atome du cycle contenant au moins deux hétérocycles différents ou différemment substitués ni condensés entre eux ni condensés avec un carbocycle commun ou un système carbocyclique commun

Abrégé

The present invention relates to a yeast or filamentous fungal cell producing at least one secreted protein of interest, wherein said cell comprises at least one additional fungal gene showing increased expression and/or overexpression, showing reduced expression and/or inactivation, wherein said gene improves the production of the at least one secreted protein of interest. The present invention further relates to respective methods for production and uses of the yeast or filamentous fungal cells.

Classes IPC  ?

• C12P 21/00 - Préparation de peptides ou de protéines
• C07K 14/37 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de champignons
• C07K 14/39 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de champignons provenant de levures
• C12N 9/90 - Isomérases (5.)
• C12N 15/80 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons

Abrégé

The present invention relates to a yeast cell producing at least one secreted protein of interest, wherein said cell comprises at least one additional fungal gene showing increased expression and/or overexpression, showing reduced expression and/or inactivation, wherein said gene improves the production of the at least one secreted protein of interest. The present invention further relates to respective methods for production and uses of the yeast cell.

Classes IPC  ?

• C12P 21/00 - Préparation de peptides ou de protéines
• C07K 14/37 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de champignons
• C07K 14/39 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de champignons provenant de levures
• C12N 9/90 - Isomérases (5.)
• C12N 15/80 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons

Abrégé

The invention relates to the field of bioconjugation of functional entities (payloads) to targeting agents, in particular biological targeting agents, such as antibody drug conjugates (ADCs), where one or more payload molecules are conjugated to a targeting agent, as for example a monoclonal antibody. More particularly, the present invention relates to novel hydrophilic tetrazine molecules and their preparation, which tetrazines allow a more efficient conjugation of payload molecules to targeting agents, like monoclonal antibodies. The present invention also relates to particular tetrazine intermediates useful for the preparation of correspondingly functionalized payload molecules. The present invention also relates to respective conjugates, in particular bio-conjugates and methods of their preparation. The invention also relates to the use of such conjugates of the present invention for use in medicine, to corresponding pharmaceutical compositions as well as to corresponding diagnostic and analytical kits.

Classes IPC  ?

• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
• C07D 257/08 - Cycles à six chaînons
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 498/14 - Systèmes condensés en ortho
• C07F 9/6524 - Composés hétérocycliques, p.ex. contenant du phosphore comme hétéro-atome du cycle comportant au moins quatre atomes d'azote comme uniques hétéro-atomes du cycle
• C07F 9/6558 - Composés hétérocycliques, p.ex. contenant du phosphore comme hétéro-atome du cycle contenant au moins deux hétérocycles différents ou différemment substitués ni condensés entre eux ni condensés avec un carbocycle commun ou un système carbocyclique commun

Abrégé

Disclosed herein is a method of operating a microfluidic system, a microfluidic system for manipulating sample objects, and a control system for operating a microfluidic system. The method according to the invention is for operating a microfluidic system that comprises a manipulation zone for manipulating sample objects flowing through the manipulation zone, a first detection zone arranged upstream of or in the manipulation zone and a second detection zone arranged upstream of, in or downstream of the manipulation zone. A first count is determined that characterizes a number of sample objects flowing through the first detection zone. Sample objects are manipulated in the manipulation zone. A second count is determined that characterizes a number of sample objects flowing through the second detection zone. One or more manipulation parameters for manipulating the sample objects in the manipulation zone are adjusted based on the first count and the second count.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
• G01N 15/14 - Recherche par des moyens électro-optiques
• G01N 35/08 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant un courant d'échantillons discrets circulant dans une canalisation, p.ex. analyse à injection dans un écoulement
• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie

Abrégé

The present invention relates to a method for diagnosing pancreatic cancer in a subject comprising determining the abundance of several Microbiome species in a faecal sample from said subject, and identifying the subject as having pancreatic cancer when the profile of abundance for the analysed species corresponds to a profile of abundance of the analysed species of a pancreatic cancer reference group, or not having pancreatic cancer when the profile of abundance for the analysed species corresponds to a profile of abundance of the analysed species of a reference group not having pancreatic cancer, as well as to a kit and its use for the diagnosis of pancreatic cancer.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries

Abrégé

The present invention relates to a method for diagnosing pancreatic cancer in a subject comprising determining the abundance of several Microbiome species in a faecal sample from said subject, and identifying the subject as having pancreatic cancer when the profile of abundance for the analysed species corresponds to a profile of abundance of the analysed species of a pancreatic cancer reference group, or not having pancreatic cancer when the profile of abundance for the analysed species corresponds to a profile of abundance of the analysed species of a reference group not having pancreatic cancer, as well as to a kit and its use for the diagnosis of pancreatic cancer.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries

Abrégé

The present invention is concerned with orthogonal translation systems which allow for the site-specific introduction of non-canonical amino acid residues into a target protein (POI) in a POI-mRNA-selective manner. Specifically, the present invention relates to assembler fusion proteins which bring an RNA-targeting polypeptide (RNA-TP) segment and an orthogonal aminoacyl tRNA synthetase (O-RS) segment into spatial proximity of one another, either by direct linkage in RNA-TP/O-RS fusion proteins, or though the action of “assemblers” fused to each of these segments in assembler fusion proteins (AFPs). The invention also relates to AFP combinations and nucleic acid molecules comprising a POI-encoding sequence together with a targeting nucleotide sequence that is able to interact with an RNA-TP. The invention further relates to nucleic acid molecules, expression cassettes and expression vectors encoding said RNA-TP/O-RS fusion proteins or AFPs, cells comprising same, as well as methods and kits for translationally preparing POIs.

Classes IPC  ?

• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p.ex. glutathion
• C12N 9/00 - Enzymes, p.ex. ligases (6.); Proenzymes; Compositions les contenant; Procédés pour préparer, activer, inhiber, séparer ou purifier des enzymes

Abrégé

The present invention relates to a carrier conjugate comprising at least one dodecin protein unit conjugated with at least one hapten and/or immunogenic and/or enzymatically active moiety. Further, the invention relates to a method for producing said conjugate and a method for producing antibodies that specifically binds to a hapten and/or immunogenic moiety of the conjugate, and to a method for performing enzymatic or diagnostic assays in vitro using said conjugate. Moreover, the invention relates to the use of said conjugate for producing antibodies that specifically bind to the epitope or epitopes contained in the moiety of said conjugate and use of said conjugate for performing enzymatic or diagnostic assays in vitro.

Classes IPC  ?

• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p.ex. séquences de liaison peptidiques vulnérable aux protéases
• C12P 21/00 - Préparation de peptides ou de protéines
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C07K 14/35 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)

Abrégé

A microscope (1) for imaging one or more samples (70) is disclosed. The microscope (1) comprises a sample holder (30) comprising a receptacle (40) for holding the one or more samples (70), at least one illumination objective lens (10) for illuminating the one or more samples (70) with an illumination beam in an illumination light path from underneath the sample holder (30) and at least two detection objective lenses (20) arranged at the side of the sample holder (30) and for collecting light emitted from the one or more samples to image the one or more samples (70) with one or more detectors (25).

Classes IPC  ?

• G02B 21/00 - Microscopes
• G02B 21/36 - Microscopes aménagés pour la photographie ou la projection

Abrégé

The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and/or treatment of bacterial infections and antibacterial-induced dysfunctions. The invention is based on the identification of compounds that prevent antibacterial effects of antibiotics on microbiome-bacterial species, while retaining antibacterial effects of antibiotics on pathogenic bacteria. The invention also pertains to pharmaceutical compositions comprising antibiotics and antibiotic antidotes for the protection of commensal microbiome-bacteria. Thus, this invention relates to compounds and pharmaceutical combinations useful to prevent antibiotic-induced adverse effects on the gut microbiome. Furthermore provided are methods for preventing an adverse effect on a gut microbiome using the compounds and/or pharmaceutical compositions of this invention.

Classes IPC  ?

• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61K 31/7052 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides 
• A61K 31/65 - Tétracyclines 
• A61P 1/14 - Eupeptiques, p.ex. acides, enzymes, orexigènes, antidyspeptiques, toniques, antiflatulants
• A61K 31/196 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p.ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil 

Abrégé

The present invention relates to the field of genome editing and in particular to a new proteinaceous system for hybridization-based precision genome cleavage and editing in a cell, tissue, and/or sample, as well as respective methods, systems and diagnostic and therapeutic uses thereof.

Classes IPC  ?

• C12N 9/22 - Ribonucléases
• C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées

Abrégé

The present invention pertains to methods for obtaining captured polynucleotide fragments. Further provided are methods for obtaining rearranged captured polynucleotide fragments. The present invention also relates to methods for the identification of at least one compound, at least one protein, and/or at least one secondary metabolite having biological activity. Kits for performing the above methods, methods of treatment using the compounds as screened with the methods for identification of at least one compound having biological activity, as well as pharmaceutical compositions thereof, are also provided.

Classes IPC  ?

• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p.ex. kinases (2.7)
• C12N 9/22 - Ribonucléases
• C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p.ex. pour test de réaction en chaîne par polymérase [PCR]

Abrégé

The invention regards a method for screening for interactions between two compounds provided in libraries. The invention in particular provides a method for screening interactions, such as a binding between two molecules or macromolecules, that is not limited to a classical screening by bait and prey setup, and therefore allows for a high-complexity screening of large candidate libraries, including screening for immunological interactions such as interactions between T-cells and antigen presenting cells, or B-cells and their antigenic targets.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
• C12Q 1/6818 - Tests d’hybridation caractérisés par les moyens de détection impliquant l’interaction de plusieurs marqueurs, p.ex. transfert d’énergie de résonance

Abrégé

The invention provides a method for quantifying the number of target entities that were successfully encapsulated into a microfluidic compartment such as a microfluidic droplet. The invention is predicated upon a continuous quantifiable detectable signal corresponding to the quantity of entities encapsulated in a microfluidic compartment. The present invention is useful in the context of high throughput microfluidic screening approaches which require thorough signal normalization in order to reliably improve signal to noise ratio and to reliably identify screening hits.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
• G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées

Abrégé

The invention relates to electron microscopy (EM) supports for in situ cryo-electron tomography, particularly to contactless and mask-free photo-micropatterning of EM grids for site-specific deposition of extracellular matrix-related proteins for micromachining by cryo-focused ion beam milling. The new EM supports allow for analysis of intracellular organization, permitting direct correlation of cell biology and biomechanics by 3D-structural characterization of the underlying molecular machinery in cellulo.

Classes IPC  ?

• H01J 37/20 - Moyens de support ou de mise en position de l'objet ou du matériau; Moyens de réglage de diaphragmes ou de lentilles associées au support
• H01J 37/28 - Microscopes électroniques ou ioniques; Tubes à diffraction d'électrons ou d'ions avec faisceaux de balayage

Abrégé

The present invention relates to improved adeno-associated virus (AAV) particles for gene delivery and gene therapy. Provided are adeno associated virus (AAV) particles that comprise a modified capsid. The present invention further relates to methods for producing the improved AAV particles of this invention by removing natural binding sites in adeno associated virus (AAV) capsids and introducing ligand binding sites into said capsid to provide AAVs that transduce only particular cells of interest. An additional aspect of the present invention relates to modified AAV particles for use in the treatment of a disease and methods for treating a disease, comprising administering the modified AAV particles to a subject in need thereof. Yet a further aspect of this invention relates to the AAV particles of this invention for the transfection of cells, for example as a gene delivery tool in basic research.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
• C12N 15/86 - Vecteurs viraux

Abrégé

The present invention provides a method for detecting structural variations (SV) within genomes of single cells or population of single cells by integrating a three-layered information of sequencing read depth, read strand orientation and haplotype phase. The method of the invention can detect deletions, duplications, polyploidies, translocations, inversions, and copy number neutral loss of heterozygosity (CNN-LOH), and more. The method of the invention can fully karyotype a genome comprehensively, and may be applied in research and clinical approaches. For example, the methods of the invention are useful for analysing cellular samples of patients for diagnosing or aiding a diagnosis, in reproductive medicine to detect embryonic abnormalities, or during therapeutic approaches based on cellular therapies to quality control genetically engineered cells, such as in adoptive T cell therapy and others. The method of the invention may further be applied in research to decipher the karyotypes of cellular models (cell lines), patient samples, or to further unravel genetic and mechanistic pathways leading to the generation of any SV within genomes.

Classes IPC  ?

• G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
• G16B 30/00 - TIC spécialement adaptées à l’analyse de séquences impliquant des nucléotides ou des aminoacides
• G16B 50/00 - TIC pour la programmation d’outils ou de systèmes de bases de données spécialement adaptées à la bio-informatique

Abrégé

The present invention relates to a core-shell particle comprising a core cross-linked polymeric micelle (CCPM), and one or more iron oxide nanoparticles (IONs), wherein the one or more ION is located in the core of the CCPM. Further provided are methods for producing the core-shell particle, compositions comprising the same, the core-shell particle or the composition for use in medicine, and methods for modulating the activity of immune cells and methods of treating dysregulation of the immune system, cancer, anemia and nerve injuries.

Classes IPC  ?

• A61K 9/51 - Nanocapsules
• A61K 33/26 - Fer; Ses composés
• A61P 35/00 - Agents anticancéreux

Produits et services

Software for use in the fields of genetics, genomics, proteomics and biomedicine. Software design and development for use in the fields of genetics, genomics, proteomics and biomedicine; maintenance of computer software for use in the fields of genetics, genomics, proteomics and biomedicine; design and development of computer hardware for use in the fields of genetics, genomics, proteomics and biomedicine; computer programming services in the fields of genetics, genomics, proteomics and biomedicine; consultation services relating to computer software for use in the fields of genetics, genomics, proteomics and biomedicine; consultancy in the design and development of computer hardware for use in the fields of genetics, genomics, proteomics and biomedicine; scientific and technological services in the fields of genetics, genomics, proteomics and biomedicine; scientific consultancy in the fields of genetics, genomics, proteomics and biomedicine; technological consultation services in the fields of genetics, genomics, proteomics and biomedicine; design services in the fields of genetics, genomics, proteomics and biomedicine; design consultation in the fields of genetics, genomics, proteomics and biomedicine; IT consultancy, advisory and information services in the fields of genetics, genomics, proteomics and biomedicine; provision of scientific information and scientific data relating to genetics, genomics, proteomics and biomedicine. Medical services in the fields of genetics, genomics, proteomics and biomedicine; veterinary services in the fields of genetics, genomics, proteomics and biomedicine; provision of medical information and medical data relating to genetics, genomics, proteomics and biomedicine.

Abrégé

The present invention relates to new adenoviral coat protein based delivery vehicles. They are based on a modified penton base protomers that assemble into VLPs. Exposed areas of the penton base proteins can be modified to allow the VLP to specifically bind to any target and/or to comprise any desired peptide epitope. Additional cargo, for example drugs, proteins, or nucleic acids, can reversibly or irreversibly attached to the VLP via engineered fibre protein fragments. The present invention relates to such engineered penton base protomers, engineered proteins comprising an adenovirus fibre protein N-terminal fragment specifically binding to an adenovirus fibre protein binding cleft of a penton base protomer, VLPs comprising the engineered penton base protomers and optionally engineered proteins comprising an adenovirus fibre protein N-terminal fragment specifically binding to an adenovirus fibre protein binding cleft of a penton base protomer, nucleic encoding the engineered proteins, the VLPs as well as methods of producing the proteins and VLPs.

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
• A61K 39/12 - Antigènes viraux
• C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification

Abrégé

This invention relates to novel surface modified viral capsids and recombinant virions comprising the same. Furthermore, this invention concerns intermediates for the preparation of surface modified viral capsids. The surface modified viral capsids are designed to selectively and/or more efficiently deliver gene therapy. The surface modified viral capsids, when incorporated into a recombinant virion, can be used to treat an illness that is characterized by genetic abnormality.

Classes IPC  ?

• C07D 225/02 - Composés hétérocycliques contenant des cycles de plus de sept chaînons ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle non condensés avec d'autres cycles 

Abrégé

This invention relates to novel surface modified viral capsids and recombinant virions comprising the same. Furthermore, this invention concerns intermediates for the preparation of surface modified viral capsids. The surface modified viral capsids are designed to selectively and/or more efficiently deliver gene therapy. The surface modified viral capsids, when incorporated into a recombinant virion, can be used to treat an illness that is characterized by genetic abnormality.

Classes IPC  ?

• C07D 225/02 - Composés hétérocycliques contenant des cycles de plus de sept chaînons ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle non condensés avec d'autres cycles 

Abrégé

The Sleeping Beauty (SB) transposon is an efficient non-viral tool for inserting transgenes into cells. Its broad utilization in gene therapy has been hampered by uncontrolled transposase gene activity and the inability to use transposase protein directly. The present invention concerns the finding that SB transposase spontaneously penetrates mammalian cells and can be delivered with transposon DNA to gene-modify various cell lines, embryonic, hematopoietic and induced pluripotent stem cells. The invention provides methods and compounds to apply the cell penetrating function of transposase in methods of genetically engineering cells as well as using the transposase as a shuttle for delivering cargo into a target cell or even into a target cell organelle. Genomic integration frequency can be titrated using the technology of the invention, which adds an additional layer of safety, opening opportunities for advanced applications in genetic engineering and gene therapy.

Classes IPC  ?

• C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
• C12N 9/22 - Ribonucléases

Abrégé

The present invention relates to novel transposon constructs and uses thereof. The novel transposon constructs of this invention have been developed based on structure-guided engineering approaches of the IS608 transposon. Provided are polynucleotides encoding for transposon ends, which may advantageously be used for site-specific insertion of a nucleotide sequence of interest into the genome of a target cell or a target DNA molecule. The invention provides further nucleic acids, vectors and recombinant cells encoding or containing the improved polynucleotides encoding for transposon ends, as well as a transposase system. Hence, the invention provides many tools for molecular genetic approaches for genome alteration, such as cloning strategies. Furthermore provided are medical and non-medical uses of the polynucleotides of the invention. The invention is in particular useful as a tool for gene delivery in genetically modified cell based therapeutic approaches for treating various diseases and for genetic tagging of endogenous proteins in research.

Classes IPC  ?

• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome

Abrégé

The present invention pertains to a method for identifying and/or characterizing a compound suitable for the prevention and/or treatment of a disease. The invention is based on the finding that the glycolytic enzyme Enolase 1 (ENO1) binds RNA, and its enzymatic activity is thereby regulated. The invention is further based on the finding that riboregulation of ENO1 affects cell differentiation, which plays a pivotal role in cancer. Accordingly, the invention provides a screening method for novel therapeutic compounds based on the binding of RNA to ENO1. Compounds screened according to the present invention can affect the binding of RNA to ENO1, which harbors the therapeutic potential for the treatment of diseases, in particular proliferative diseases, such as cancer. Methods of treatment using these compounds, as well as pharmaceutical compositions thereof, are also provided.

Classes IPC  ?

• C12N 9/88 - Lyases (4.)
• C12Q 1/6804 - Analyse d’acides nucléiques utilisant des immunogènes
• C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
• A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p.ex. cellulases, lactases
• A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 31/00 - Agents anti-infectieux, c. à d. antibiotiques, antiseptiques, chimiothérapeutiques
• A61P 35/00 - Agents anticancéreux
• A61P 37/02 - Immunomodulateurs
• C12N 15/60 - Lyases (4)
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides

Abrégé

The present invention pertains to a method for identifying and/or characterizing a compound suitable for the prevention and/or treatment of a disease. The invention is based on the finding that the glycolytic enzyme Enolase 1 (ENO1) binds RNA, and its enzymatic activity is thereby regulated. The invention is further based on the finding that riboregulation of ENO1 affects cell differentiation, which plays a pivotal role in cancer. Accordingly, the invention provides a screening method for novel therapeutic compounds based on the binding of RNA to ENO1. Compounds screened according to the present invention can affect the binding of RNA to ENO1, which harbors the therapeutic potential for the treatment of diseases, in particular proliferative diseases, such as cancer. Methods of treatment using these compounds, as well as pharmaceutical compositions thereof, are also provided.

Classes IPC  ?

• C12N 9/88 - Lyases (4.)

Produits et services

Downloadable software for use in the fields of genetics, genomics, proteomics and biomedicine Software design and development for use in the fields of genetics, genomics, proteomics and biomedicine; Maintenance of computer software for use in the fields of genetics, genomics, proteomics and biomedicine; Design and development of computer hardware for use in the fields of genetics, genomics, proteomics and biomedicine; Computer programming services in the fields of genetics, genomics, proteomics and biomedicine; Consultation services relating to computer software for use in the fields of genetics, genomics, proteomics and biomedicine; consultancy in the design and development of computer hardware for use in the fields of genetics, genomics, proteomics and biomedicine; scientific and technological services in the fields of genetics, genomics, proteomics and biomedicine, namely, scientific research, analysis, and testing in the fields of genetics, genomics, proteomics and biomedicine; Scientific research consultation in the fields of genetics, genomics, proteomics and biomedicine; technological consultation services in the fields of genetics, genomics, proteomics and biomedicine; software design services in the fields of genetics, genomics, proteomics and biomedicine; software design consultation in the fields of genetics, genomics, proteomics and biomedicine; computer technology consultancy, advisory and information services in the fields of genetics, genomics, proteomics and biomedicine; providing of scientific information and scientific data in the fields of genetics, genomics, proteomics and biomedicine Medical services in the fields of genetics, genomics, proteomics and biomedicine; veterinary services in the fields of genetics, genomics, proteomics and biomedicine; provision of medical information and medical data relating to genetics, genomics, proteomics and biomedicine

Produits et services

Chemicals used in industry, containing paramagnetic particles, in particular for use in the pharmaceutical industry Chemico-pharmaceutical preparations, containing paramagnetic particles, for use in the homogenization of protein samples which are intended for diagnostic tests Scientific laboratory services using paramagnetic particles, especially for the pharmaceutical industry; scientific research using paramagnetic particles, especially for the pharmaceutical industry

Produits et services

Software for use in the fields of genetics, genomics, proteomics and biomedicine; electronic publications in the fields of genetics, genomics, proteomics and biomedicine; electronic data processing apparatus for use in the fields of genetics, genomics, proteomics and biomedicine. Printed matter in the fields of genetics, genomics, proteomics and biomedicine; printed reports in the fields of genetics, genomics, proteomics and biomedicine; journals in the fields of genetics, genomics, proteomics and biomedicine; instructional and teaching materials for use in the fields of genetics, genomics, proteomics and biomedicine. Publishing services in the fields of genetics, genomics, proteomics and biomedicine; educational services in the fields of genetics, genomics, proteomics and biomedicine. Software design and development for use in the fields of genetics, genomics, proteomics and biomedicine; maintenance of computer software for use in the fields of genetics, genomics, proteomics and biomedicine; design and development of computer hardware for use in the fields of genetics, genomics, proteomics and biomedicine; computer programming services in the fields of genetics, genomics, proteomics and biomedicine; consultation services relating to computer software for use in the fields of genetics, genomics, proteomics and biomedicine; consultation services relating to the design and development of computer hardware for use in the fields of genetics, genomics, proteomics and biomedicine; scientific and technological services in the fields of genetics, genomics, proteomics and biomedicine; scientific consultancy in the fields of genetics, genomics, proteomics and biomedicine; technological consultation services in the fields of genetics, genomics, proteomics and biomedicine; design services in the fields of genetics, genomics, proteomics and biomedicine; design consultation in the fields of genetics, genomics, proteomics and biomedicine; IT consultancy, advisory and information services in the fields of genetics, genomics, proteomics and biomedicine; provision of scientific information and scientific data relating to genetics, genomics, proteomics and biomedicine. Medical services in the fields of genetics, genomics, proteomics and biomedicine; veterinary services in the fields of genetics, genomics, proteomics and biomedicine; provision of medical information and medical data relating to genetics, genomics, proteomics and biomedicine.

Abrégé

The present invention pertains to a new method for the prognosis, diagnosis, stratification and/or monitoring of a therapy of a disorder in a subject. The method is based on the determination of the level of at least one first biomarker indicative and/or selective for the status and/or activity of the pathway regulating N6-methyladenosine (m6A) mRNA modification, and the determination of the level, mutation status, and/or activity of at least one second biomarker indicative and/or selective for the status and/or activity of the pathway regulating 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U)-tRNA modification as combined biomarkers. The new biomarkers of the invention allow diagnosing and even stratifying of a disorder in a patient, estimating a patient's prognosis, and monitoring therapy success of patients, in particular of cancer patients, such as breast cancer patients. Further provided are kits for the prognosis, diagnosis, and/or monitoring of a disease, condition or disorder in a subject. The invention also pertains to a compound for use in the treatment of a disease, condition or disorder, wherein the compound specifically reduces or enhances the level, mutation status, and/or activity of a gene, mRNA or protein regulating m6A mRNA modification in a cell, and/or a gene, mRNA or protein regulating mcm5s2U-tRNA modification in a cell.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention pertains to a new method for the prognosis, diagnosis, stratification and/or monitoring of a therapy of a disorder in a subject. The method is based on the determination of the level of at least one first biomarker indicative and/or selective for the status and/or activity of the pathway regulating N6-methyladenosine (m6A) mRNA modification, and the determination of the level, mutation status, and/or activity of at least one second biomarker indicative and/or selective for the status and/or activity of the pathway regulating 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U)-tRNA modification as combined biomarkers. The new biomarkers of the invention allow diagnosing and even stratifying of a disorder in a patient, estimating a patient's prognosis, and monitoring therapy success of patients, in particular of cancer patients, such as breast cancer patients. Further provided are kits for the prognosis, diagnosis, and/or monitoring of a disease, condition or disorder in a subject. The invention also pertains to a compound for use in the treatment of a disease, condition or disorder, wherein the compound specifically reduces or enhances the level, mutation status, and/or activity of a gene, mRNA or protein regulating m6A mRNA modification in a cell, and/or a gene, mRNA or protein regulating mcm5s2U-tRNA modification in a cell.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention pertains to novel analgesics useful for treating mechanical pain. The invention suggests the use of inhibitors of α-tubulin acetylation for inhibition of neurological sensations that are mediated by sensory neurons. The perception of mechanical pain is can be modulated by altering the α-tubulin acetylation, in context of the invention in particular by modulation of the expression and/or activity of the enzyme α-tubulin acetyltransferase (Atat). The invention provides the medical application of α-tubulin acetyltransferase inhibitors as analgesics and a screening method for the identification of compounds useful in the treatment of pain.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes
• A01K 67/027 - Nouvelles races de vertébrés
• G01N 33/573 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour enzymes ou isoenzymes

Abrégé

Methods of treatment, genetic screening, and disease models for heart conditions associated with RBM20 deficiency are disclosed. In particular, methods of treating heart conditions associated with RBM20 deficiency, including RBM20-dependent dilated cardiomyopathy and heart failure with compounds that upregulate expression of RBM20, such as all-trans retinoic acid are provided. Also disclosed are methods of genetic screening to detect the presence of a P633L mutation in RBM20 in order to identify individuals having a genetic predisposition to developing RBM20-dependent DCM. Induced pluripotent stem cell-derived cardiomyocytes (IPSC-CMs) produced by differentiation of IPSCs comprising at least one RBM20 allele encoding a P633L mutation and methods of using them in screening for therapeutics for treating RBM20-dependent DCM are also disclosed.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• A61K 31/203 - Acides rétinoïques
• A61P 9/04 - Agents inotropes, c. à d. stimulants de la contraction cardiaque; Médicaments pour le traitement de l'insuffisance cardiaque

Produits et services

Software for use in the fields of genetics, genomics and biomedicine; electronic publications in the fields of genetics, genomics and biomedicine; electronic data processing apparatus for use in the fields of genetics, genomics and biomedicine. Printed matter in the fields of genetics, genomics and biomedicine; printed reports in the fields of genetics, genomics and biomedicine; journals in the fields of genetics, genomics and biomedicine; instructional and teaching materials for use in the fields of genetics, genomics and biomedicine. Publishing services in the fields of genetics, genomics and biomedicine; educational services in the fields of genetics, genomics and biomedicine. Software design and development for use in the fields of genetics, genomics and biomedicine; maintenance of computer software for use in the fields of genetics, genomics and biomedicine; design and development of computer hardware for use in the fields of genetics, genomics and biomedicine; computer programming services in the fields of genetics, genomics and biomedicine; consultation services relating to computer software for use in the fields of genetics, genomics and biomedicine; consultation services relating to computer hardware for use in the fields of genetics, genomics and biomedicine; scientific and technological services in the fields of genetics, genomics and biomedicine; scientific consultancy in the fields of genetics, genomics and biomedicine; technological consultation services in the fields of genetics, genomics and biomedicine; design services in the fields of genetics, genomics and biomedicine; design consultation in the fields of genetics, genomics and biomedicine; IT consultancy, advisory and information services in the fields of genetics, genomics and biomedicine; provision of scientific information and scientific data relating to genetics, genomics and biomedicine; genetic, genomic and biomedical research services relating to the fields of agriculture and aquaculture. Medical services in the fields of genetics, genomics and biomedicine; veterinary services in the fields of genetics, genomics and biomedicine; provision of medical information and medical data relating to genetics, genomics and biomedicine.

Abrégé

A sample thickness measuring arrangement and method for measuring a thickness of a sample are proposed. The sample thickness measuring arrangement comprises a sample thickness measuring unit for measuring the thickness of a sample based on interferometry. Furthermore, it comprises a cryostat comprising a coolant reservoir and a sample observation unit for observing characteristics of a sample. The sample observation unit comprises a tube enclosing an observation volume, a thermal tube insulation layer and a window arrangement. The tube is open at a distal end and at a proximal end. The distal end of the tube is arranged. within a storage volume of the coolant reservoir. The tube has two lateral openings in its tube walls at opposing sides with regards to the observation volume. The tube walls are covered at their external side with the thermal tube insulation layer having two openings adjacent to the openings in the tube walls. The window arrangement comprises two opposing panes, each pane being arranged at one of the openings in the thermal insulation layer. The panes are transparent to light of a laser beam. The proposed approach enable precise and stable sample thickness measurements at cryogenic temperatures.

Classes IPC  ?

• G01B 11/06 - Dispositions pour la mesure caractérisées par l'utilisation de techniques optiques pour mesurer la longueur, la largeur ou l'épaisseur pour mesurer l'épaisseur
• G01N 1/42 - Traitement à basse température des échantillons, p.ex. cryofixation

Produits et services

Downloadable software for use in the fields of genetics, genomics and biomedicine; electronic publications in the fields of genetics, genomics and biomedicine; electronic data processing apparatus for use in the fields of genetics, genomics and biomedicine Printed matter, namely, newspapers, photographs, magazines, books, printed periodicals, newsletters, and brochures in the fields of genetics, genomics and biomedicine; printed reports in the fields of genetics, genomics and biomedicine; printed journals in the fields of genetics, genomics and biomedicine; printed instructional and teaching materials for use in the fields of genetics, genomics and biomedicine Publication of texts, books, and journals in the fields of genetics, genomics and biomedicine; educational services, namely, providing classes, seminars, workshops in the fields of genetics, genomics and biomedicine Software design and development for use in the fields of genetics, genomics and biomedicine; maintenance of computer software for use in the fields of genetics, genomics and biomedicine; design and development of computer hardware for use in the fields of genetics, genomics and biomedicine; computer programming services in the fields of genetics, genomics and biomedicine; consultation services relating to computer software for use in the fields of genetics, genomics and biomedicine; consultation services relating to computer hardware for use in the fields of genetics, genomics and biomedicine; scientific and technological services, namely, scientific research, analysis, testing in the fields of genetics, genomics and biomedicine; scientific consultancy in the fields of genetics, genomics and biomedicine; technological consultation in the technology fields of genetics, genomics and biomedicine; design services in the fields of genetics, genomics and biomedicine; design consultation in the fields of genetics, genomics and biomedicine; Information technology consultancy and advisory in the technology fields of genetics, genomics and biomedicine; providing technology information in the fields of genetics, genomics, proteomics and biomedicine; provision of scientific information in the fields of genetics, genomics and biomedicine; scientific research in the fields of genetics and genomics in relation to agriculture and aquaculture; biomedical research services relating to the fields of agriculture and aquaculture Medical services in the fields of genetics, genomics and biomedicine; veterinary services in the fields of genetics, genomics and biomedicine; provision of medical information relating to genetics, genomics and biomedicine

Abrégé

90 M/60097-PCT Abstract The present invention is concerned with efficient orthogonal translation systems for eukaryotic cells. Specifically, the invention relates to eukaryotic cells comprising polynucleotides encoding a prokaryotic tRNA synthetase (pRS) and an RNA molecule comprising a prokaryotic tRNA (ptRNA) and one or more than one ribozyme (termed "ptRNA-ribozyme" herein). It also relates to a method for expressing a polypeptide of interest (POI) comprising one or more non-canonical amino acid (ncAA) residues by such eukaryotic cells, and to kits useful in such method. The invention further relates to polynucleotides encoding the ptRNA-ribozyme.

Classes IPC  ?

• C12N 15/01 - Préparation de mutants sans introduction de matériel génétique étranger; Procédés de criblage à cet effet
• C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p.ex. glutathion

Abrégé

90 M/60097-PCT Abstract The present invention is concerned with efficient orthogonal translation systems for eukaryotic cells. Specifically, the invention relates to eukaryotic cells comprising polynucleotides encoding a prokaryotic tRNA synthetase (pRS) and an RNA molecule comprising a prokaryotic tRNA (ptRNA) and one or more than one ribozyme (termed "ptRNA-ribozyme" herein). It also relates to a method for expressing a polypeptide of interest (POI) comprising one or more non-canonical amino acid (ncAA) residues by such eukaryotic cells, and to kits useful in such method. The invention further relates to polynucleotides encoding the ptRNA-ribozyme.

Classes IPC  ?

• C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p.ex. glutathion
• C12N 15/01 - Préparation de mutants sans introduction de matériel génétique étranger; Procédés de criblage à cet effet

Produits et services

Software for use in the fields of genetics, genomics and biomedicine; electronic publications in the fields of genetics, genomics and biomedicine; electronic data processing apparatus for use in the fields of genetics, genomics and biomedicine. Printed matter in the fields of genetics, genomics and biomedicine; printed reports in the fields of genetics, genomics and biomedicine; journals in the fields of genetics, genomics and biomedicine; instructional and teaching materials for use in the fields of genetics, genomics and biomedicine. Maintenance of computer hardware for use in the fields of genetics, genomics and biomedicine. Publishing services in the fields of genetics, genomics and biomedicine; educational services in the fields of genetics, genomics and biomedicine. Software design and development for use in the fields of genetics, genomics and biomedicine; maintenance of computer software for use in the fields of genetics, genomics and biomedicine; design and development of computer hardware for use in the fields of genetics, genomics and biomedicine; computer programming services in the fields of genetics, genomics and biomedicine; consultation services relating to computer software for use in the fields of genetics, genomics and biomedicine; consultancy in the design and development of computer hardware for use in the fields of genetics, genomics and biomedicine; scientific and technological services in the fields of genetics, genomics and biomedicine; scientific consultancy in the fields of genetics, genomics and biomedicine; technological consultation services in the fields of genetics, genomics and biomedicine; design services in the fields of genetics, genomics and biomedicine; design consultation in the fields of genetics, genomics and biomedicine; IT consultancy, advisory and information services in the fields of genetics, genomics and biomedicine; provision of scientific information and scientific data relating to genetics, genomics and biomedicine. Medical services in the fields of genetics, genomics and biomedicine; veterinary services in the fields of genetics, genomics and biomedicine; provision of medical information and medical data relating to genetics, genomics and biomedicine.

Produits et services

Downloadable software for use in the fields of genetics, genomics, proteomics and biomedicine; downloadable electronic publications in the nature of pdfs, journals, and books in the fields of genetics, genomics, proteomics and biomedicine; electronic data processing apparatus for use in the fields of genetics, genomics, proteomics and biomedicine Printed matter, namely, newspapers, photographs, magazines, books, printed periodicals, newsletters, and brochures in the fields of genetics, genomics, proteomics and biomedicine; printed reports in the field of genetics, genomics, proteomics and biomedicine; printed journals in the fields of genetics, genomics, proteomics and biomedicine; printed instructional and teaching materials for use in the fields of genetics, genomics, proteomics and biomedicine Publication of texts, books, and journals in the fields of genetics, genomics, proteomics and biomedicine; educational services, namely, providing classes, seminars, workshops in the fields of genetic, genomics, proteomics and biomedicine Software design and development for use in the fields of genetics, genomics, proteomics and biomedicine; maintenance of computer software for use in the fields of genetics, genomics, proteomics and biomedicine; design and development of computer hardware for use in the fields of genetics, genomics, proteomics and biomedicine; computer programming services in the fields of genetics, genomics, proteomics and biomedicine; consultation services relating to computer software for use in the fields of genetics, genomics, proteomics and biomedicine; consultation services relating to the design and development of computer hardware for use in the fields of genetics, genomics, proteomics and biomedicine; scientific and technological services, namely scientific research, analysis, and testing in the fields of genetics, genomics, proteomics and biomedicine; scientific consultancy in the fields of genetics, genomics, proteomics and biomedicine; technological consultation in the technology fields of genetics, genomics, proteomics and biomedicine; design services in the fields of genetics, genomics, proteomics and biomedicine; design consultation in the fields of genetics, genomics, proteomics and biomedicine; Information technology consultancy and advisory in the technology fields of genetics, genomics, proteomics and biomedicine; providing technology information in the fields of genetics, genomics, proteomics and biomedicine; provision of scientific information in the fields of genetics, genomics, proteomics and biomedicine Medical services in the fields of genetics, genomics, proteomics and biomedicine; veterinary services in the fields of genetics, genomics, proteomics and biomedicine; provision of medical information relating to genetics, genomics, proteomics and biomedicine

Abrégé

A microscope is described, having an illumination light path for illuminating a sample or object and a viewing light path for viewing the sample. The microscope comprises an illumination light path focusing arrangement in the illumination light path, which comprises a scanning module for generating a substantially two-dimensional sample or object illumination region extending along an illumination direction of the illumination light path and a direction transverse thereto. The microscope further comprises an illumination region-confining device in the illumination light path for selectively illuminating a portion of the substantially two-dimensional object illumination region, wherein the portion of the substantially two-dimensional object illumination region is confined at least in the illumination direction and/or in the direction transversely thereto.

Classes IPC  ?

• G02B 21/00 - Microscopes
• G01N 21/64 - Fluorescence; Phosphorescence

Abrégé

in vitroin vitro.

Classes IPC  ?

• C07K 14/195 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries
• C07K 14/35 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)

Abrégé

The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and/or treatment of bacterial infections and antibacterial-induced dysfunctions. The invention is based on the identification of compounds that prevent antibacterial effects of antibiotics on microbiome-bacterial species, while retaining antibacterial effects of antibiotics on pathogenic bacteria. The invention also pertains to pharmaceutical compositions comprising antibiotics and antibiotic antidotes for the protection of commensal microbiome-bacteria. Thus, this invention relates to compounds and pharmaceutical combinations useful to prevent antibiotic-induced adverse effects on the gut microbiome. Furthermore provided are methods for preventing an adverse effect on a gut microbiome using the compounds and/or pharmaceutical compositions of this invention.

Classes IPC  ?

• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques 
• A61K 31/05 - Phénols
• A61K 31/196 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p.ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil 
• A61K 31/197 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p.ex. acide gamma-aminobutyrique (GABA), bêta-alanine, acide epsilon-aminocaproïque, acide pantothénique
• A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
• A61K 31/37 - Coumarines, p.ex. psoralène
• A61K 31/4152 - 1,2-Diazoles ayant des groupes oxo liés directement à l'hétérocycle, p.ex. antipyrine, phénylbutazone, sulfinpyrazone
• A61K 31/65 - Tétracyclines 
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61K 31/7052 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides 
• A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides  contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A61P 1/14 - Eupeptiques, p.ex. acides, enzymes, orexigènes, antidyspeptiques, toniques, antiflatulants

Abrégé

The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and/or treatment of bacterial infections and antibacterial-induced dysfunctions. The invention is based on the identification of compounds that prevent antibacterial effects of antibiotics on microbiome-bacterial species, while retaining antibacterial effects of antibiotics on pathogenic bacteria. The invention also pertains to pharmaceutical compositions comprising antibiotics and antibiotic antidotes for the protection of commensal microbiome-bacteria. Thus, this invention relates to compounds and pharmaceutical combinations useful to prevent antibiotic-induced adverse effects on the gut microbiome. Furthermore provided are methods for preventing an adverse effect on a gut microbiome using the compounds and/or pharmaceutical compositions of this invention.

Classes IPC  ?

• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques 
• A61K 31/65 - Tétracyclines 
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61K 31/7052 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides 
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A61P 1/14 - Eupeptiques, p.ex. acides, enzymes, orexigènes, antidyspeptiques, toniques, antiflatulants
• A61K 31/05 - Phénols
• A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
• A61K 31/37 - Coumarines, p.ex. psoralène
• A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides  contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
• A61K 31/196 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p.ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil 
• A61K 31/197 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p.ex. acide gamma-aminobutyrique (GABA), bêta-alanine, acide epsilon-aminocaproïque, acide pantothénique
• A61K 31/4152 - 1,2-Diazoles ayant des groupes oxo liés directement à l'hétérocycle, p.ex. antipyrine, phénylbutazone, sulfinpyrazone

Produits et services

Information technology and audio-visual, multimedia and photographic devices. Scientific and technological services. Medical services; veterinary services; human hygiene and beauty care; hygienic and beauty care for animals; agriculture, aquaculture, horticulture and forestry services.

Abrégé

E. coli isolates. A second set of compounds combines the polymyxin colistin with loperamide, a rifamycin, or a macrolide. Importantly, this invention relates to combinations that enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development efforts in order to prevent major side effects of antibacterial strategies. This invention also relates to pharmaceutical combinations useful to prevent an adverse effect on the gut microbiome, induced by the use of antibacterial compounds.

Classes IPC  ?

• C12Q 1/18 - Test de l'activité antimicrobienne d'un matériau
• A61K 31/11 - Aldéhydes
• A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
• A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p.ex. éthers en couronne, guanadrel
• A61K 31/445 - Pipéridines non condensées, p.ex. pipérocaïne
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
• A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p.ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
• A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides  contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
• A61K 38/12 - Peptides cycliques
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61P 31/04 - Agents antibactériens

Abrégé

The present invention relates to improved transposase polypeptides having increased solubility. The enzyme of the invention was developed based on the Sleeping Beauty (SB) transposase. The invention provides further nucleic acids, vectors and recombinant cells encoding or containing the improved transposase, as well as a transposase system. Furthermore provided are medical and non-medical uses of the transposase of the invention for gene delivery. The invention is in particular useful as a tool for gene delivery in genetically modified cell based therapeutic approaches for treating various diseases.

Classes IPC  ?

• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p.ex. kinases (2.7)

Produits et services

Downloadable software for use in compiling and analyzing patient data in the fields of genetics, genomics and biomedicine; Downloadable electronic publications in the form of e-books in the fields of genetics, genomics and biomedicine; electronic data processing apparatus for use in the fields of genetics, genomics and biomedicine Printed books in the fields of genetics, genomics and biomedicine; printed reports in the fields of genetics, genomics and biomedicine; printed journals in the fields of genetics, genomics and biomedicine; printed instructional and teaching materials for use in the fields of genetics, genomics and biomedicine * Maintenance of computer hardware for use in the fields of genetics, genomics and biomedicine * Book publishing services in the fields of genetics, genomics and biomedicine; educational services, namely, providing classes and seminars in the fields of genetics, genomics and biomedicine Software design and development for use in the fields of genetics, genomics and biomedicine; maintenance of computer software for use in the fields of genetics, genomics and biomedicine; design and development of computer hardware for use in the fields of genetics, genomics and biomedicine; [ maintenance of computer hardware for use in the fields of genetics, genomics and biomedicine; ] computer programming services in the fields of genetics, genomics and biomedicine; consultation services relating to computer software for use in the fields of genetics, genomics and biomedicine; consultancy in the design and development of computer hardware for use in the fields of genetics, genomics and biomedicine; scientific and technological services in the nature of scientific research services in the fields of genetics, genomics and biomedicine; scientific research consultancy in the fields of genetics, genomics and biomedicine; technological consultation services in the fields of computer hardware systems for the fields of genetics, genomics and biomedicine; new product design services in the fields of genetics, genomics and biomedicine; computer software design consultation in the fields of genetics, genomics and biomedicine; IT consultancy, advisory and information services in the fields of genetics, genomics and biomedicine; provision of scientific information and scientific data being scientific information relating to genetics, genomics and biomedicine

Produits et services

Software for use in the fields of genetics, genomics and biomedicine; Electronic publications in the fields of genetics, genomics and biomedicine; Electronic data processing apparatus for use in the fields of genetics, genomics and biomedicine. Printed matter in the fields of genetics, genomics and biomedicine; Printed reports in the fields of genetics, genomics and biomedicine; Journals in the fields of genetics, genomics and biomedicine; Instructional and teaching materials for use in the fields of genetics, genomics and biomedicine. Publishing services in the fields of genetics, genomics and biomedicine; Educational services in the fields of genetics, genomics and biomedicine. Software design and development for use in the fields of genetics, genomics and biomedicine; Maintenance of computer software for use in the fields of genetics, genomics and biomedicine; Design and development of computer hardware for use in the fields of genetics, genomics and biomedicine; Computer programming services in the fields of genetics, genomics and biomedicine; Consultation services relating to computer software for use in the fields of genetics, genomics and biomedicine; Consultation services relating to computer hardware for use in the fields of genetics, genomics and biomedicine; Scientific and technological services in the fields of genetics, genomics and biomedicine; Scientific consultancy in the fields of genetics, genomics and biomedicine; Technological consultation services in the fields of genetics, genomics and biomedicine; Design services in the fields of genetics, genomics and biomedicine; Design consultation in the fields of genetics, genomics and biomedicine; IT consultancy, advisory and information services in the fields of genetics, genomics and biomedicine; Provision of scientific information and scientific data relating to genetics, genomics and biomedicine; genetic, genomic and biomedical research services relating to the fields of agriculture and aquaculture. Medical services in the fields of genetics, genomics and biomedicine; Veterinary services in the fields of genetics, genomics and biomedicine; Provision of medical information and medical data relating to genetics, genomics and biomedicine.

Produits et services

Information technology and audio-visual, multimedia and photographic devices, namely, labels, cards, tags, antennas and readers for radio frequency identification credentials Scientific and technological services, namely, customized design and development of instruments and instrument parts for Microscopy, X-ray and Neutron beam imaging Medical services; veterinary services; human hygiene and beauty care; hygienic and beauty care for animals

Produits et services

Software for use in the fields of genetics, genomics, proteomics and biomedicine; Electronic publications in the fields of genetics, genomics, proteomics and biomedicine; Electronic data processing apparatus for use in the fields of genetics, genomics, proteomics and biomedicine. Printed matter in the fields of genetics, genomics, proteomics and biomedicine; Printed reports in the fields of genetics, genomics, proteomics and biomedicine; Journals in the fields of genetics, genomics, proteomics and biomedicine; Instructional and teaching materials for use in the fields of genetics, genomics, proteomics and biomedicine. Publishing services in the fields of genetics, genomics, proteomics and biomedicine; Educational services in the fields of genetics, genomics, proteomics and biomedicine. Software design and development for use in the fields of genetics, genomics, proteomics and biomedicine; Maintenance of computer software for use in the fields of genetics, genomics, proteomics and biomedicine; Design and development of computer hardware for use in the fields of genetics, genomics, proteomics and biomedicine; Computer programming services in the fields of genetics, genomics, proteomics and biomedicine; Consultation services relating to computer software for use in the fields of genetics, genomics, proteomics and biomedicine; Consultation services relating to computer hardware for use in the fields of genetics, genomics, proteomics and biomedicine; Scientific and technological services in the fields of genetics, genomics, proteomics and biomedicine; Scientific consultancy in the fields of genetics, genomics, proteomics and biomedicine; Technological consultation services in the fields of genetics, genomics, proteomics and biomedicine; Design services in the fields of genetics, genomics, proteomics and biomedicine; Design consultation in the fields of genetics, genomics, proteomics and biomedicine; IT consultancy, advisory and information services in the fields of genetics, genomics, proteomics and biomedicine; Provision of scientific information and scientific data relating to genetics, genomics, proteomics and biomedicine. Medical services in the fields of genetics, genomics, proteomics and biomedicine; Veterinary services in the fields of genetics, genomics, proteomics and biomedicine; Provision of medical information and medical data relating to genetics, genomics, proteomics and biomedicine.

Produits et services

Software for use in the fields of genetics, genomics, proteomics and biomedicine. Software design and development for use in the fields of genetics, genomics, proteomics and biomedicine; Maintenance of computer software for use in the fields of genetics, genomics, proteomics and biomedicine; Design and development of computer hardware for use in the fields of genetics, genomics, proteomics and biomedicine; Computer programming services in the fields of genetics, genomics, proteomics and biomedicine; Consultation services relating to computer software for use in the fields of genetics, genomics, proteomics and biomedicine; Consultation services relating to computer hardware for use in the fields of genetics, genomics, proteomics and biomedicine; Scientific and technological services in the fields of genetics, genomics, proteomics and biomedicine; Scientific consultancy in the fields of genetics, genomics, proteomics and biomedicine; Technological consultation services in the fields of genetics, genomics, proteomics and biomedicine; Design services in the fields of genetics, genomics, proteomics and biomedicine; Design consultation in the fields of genetics, genomics, proteomics and biomedicine; IT consultancy, advisory and information services in the fields of genetics, genomics, proteomics and biomedicine; Provision of scientific information and scientific data relating to genetics, genomics, proteomics and biomedicine. Medical services in the fields of genetics, genomics, proteomics and biomedicine; Veterinary services in the fields of genetics, genomics, proteomics and biomedicine; Provision of medical information and medical data relating to genetics, genomics, proteomics and biomedicine.

Abrégé

in cellulo in cellulo.

Classes IPC  ?

• H01J 37/20 - Moyens de support ou de mise en position de l'objet ou du matériau; Moyens de réglage de diaphragmes ou de lentilles associées au support

Abrégé

The invention relates to electron microscopy (EM) supports for in situ cryo-electron tomography, particularly to contactless and mask-free photo-micropatterning of EM grids for site-specific deposition of extracellular matrix-related proteins for micromachining by cryo- focused ion beam milling. The new EM supports allow for analysis of intracellular organization, permitting direct correlation of cell biology and biomechanics by 3D-structural characterization of the underlying molecular machinery in cellulo.

Classes IPC  ?

• H01J 37/20 - Moyens de support ou de mise en position de l'objet ou du matériau; Moyens de réglage de diaphragmes ou de lentilles associées au support

Abrégé

The present invention relates to a new nucleic acid construct capable of binding to the PB1 RNA synthesis active site of influenza polymerase. The nucleic acid construct allows capturing the structure of the transcription initiation state of influenza polymerase. The present invention further pertains to methods for obtaining images or crystallography data on an influenza polymerase in a functional or active state, methods for identifying, selecting or designing a compound which inhibits influenza RNA polymerase, and to such compounds per se. Further provided are pharmaceutical compositions comprising such compounds and the compounds or pharmaceutical compositions for use in treating, ameliorating, or preventing a disease caused by viral infections with negative-sense single stranded RNA viruses.

Classes IPC  ?

• C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p.ex. kinases (2.7)
• C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
• C30B 29/58 - Composés macromoléculaires

Abrégé

Bacteroides fragilis. Other compounds of the present invention reveal a strong inhibitory effect on a broad spectrum of bacterial species. Such compounds are useful for broad-spectrum antibiotic therapies of infections with unknown causative infecting bacterial species. Both types of compounds, especially the ones with narrow-spectrum antibacterialactivity, can further be used for modulating the microbiome composition and targeting species associated with dysbiosis and disease.

Classes IPC  ?

• A61K 31/4422 - 1,4-Dihydropyridines, p.ex. nifédipine, nicardipine
• A61K 31/137 - Arylalkylamines, p.ex. amphétamine, épinéphrine, salbutamol, éphédrine
• A61P 31/04 - Agents antibactériens

Abrégé

The present invention relates to an in-vitro model of thehuman gut microbiome, the model comprising a culture of the gut microbiome, wherein the model has a cumulative enzymatic coverage of more than 85% of the gut microbiome of a healthy human. The model facilitates metabolic modeling and enables a better understanding of the structure and function of the human gut microbiome as well as of modifications of xenobiotics by intrinsic gut microbiota, such as biotransformation and bioaccumulation. It can further be used to study the effects of variations in nutritional conditions. Importantly, the invention can also be used for diagnosing a disease, such as a gastrointestinal disorder,a proliferative disease, a metabolic disorder, a cardiovascular disease, an immunological disease, and an infectious disease.

Classes IPC  ?

• C12N 1/20 - Bactéries; Leurs milieux de culture
• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
• C12Q 1/04 - Détermination de la présence ou du type de micro-organisme; Emploi de milieux sélectifs pour tester des antibiotiques ou des bactéricides; Compositions à cet effet contenant un indicateur chimique

Produits et services

Software for use in the fields of genetics, genomics and biomedicine; Electronic publications in the fields of genetics, genomics and biomedicine; Electronic data processing apparatus for use in the fields of genetics, genomics and biomedicine. Printed matter in the fields of genetics, genomics and biomedicine; Printed reports in the fields of genetics, genomics and biomedicine; Journals in the fields of genetics, genomics and biomedicine; Instructional and teaching materials for use in the fields of genetics, genomics and biomedicine. Publishing services in the fields of genetics, genomics and biomedicine; Educational services in the fields of genetics, genomics and biomedicine. Software design and development for use in the fields of genetics, genomics and biomedicine; Maintenance of computer software for use in the fields of genetics, genomics and biomedicine; Design and development of computer hardware for use in the fields of genetics, genomics and biomedicine; Maintenance of computer hardware for use in the fields of genetics, genomics and biomedicine; Computer programming services in the fields of genetics, genomics and biomedicine; Consultation services relating to computer software for use in the fields of genetics, genomics and biomedicine; Consultation services relating to computer hardware for use in the fields of genetics, genomics and biomedicine; Scientific and technological services in the fields of genetics, genomics and biomedicine; Scientific consultancy in the fields of genetics, genomics and biomedicine; Technological consultation services in the fields of genetics, genomics and biomedicine; Design services in the fields of genetics, genomics and biomedicine; Design consultation in the fields of genetics, genomics and biomedicine; IT consultancy, advisory and information services in the fields of genetics, genomics and biomedicine; Provision of scientific information and scientific data relating to genetics, genomics and biomedicine. Medical services in the fields of genetics, genomics and biomedicine; Veterinary services in the fields of genetics, genomics and biomedicine; Provision of medical information and medical data relating to genetics, genomics and biomedicine.

Produits et services

Software for use in the fields of genetics, genomics and biomedicine; Electronic publications in the fields of genetics, genomics and biomedicine; Electronic data processing apparatus for use in the fields of genetics, genomics and biomedicine. Printed matter in the fields of genetics, genomics and biomedicine; Printed reports in the fields of genetics, genomics and biomedicine; Journals in the fields of genetics, genomics and biomedicine; Instructional and teaching materials for use in the fields of genetics, genomics and biomedicine. Publishing services in the fields of genetics, genomics and biomedicine; Educational services in the fields of genetics, genomics and biomedicine. Software design and development for use in the fields of genetics, genomics and biomedicine; Maintenance of computer software for use in the fields of genetics, genomics and biomedicine; Design and development of computer hardware for use in the fields of genetics, genomics and biomedicine; Maintenance of computer hardware for use in the fields of genetics, genomics and biomedicine; Computer programming services in the fields of genetics, genomics and biomedicine; Consultation services relating to computer software for use in the fields of genetics, genomics and biomedicine; Consultation services relating to computer hardware for use in the fields of genetics, genomics and biomedicine; Scientific and technological services in the fields of genetics, genomics and biomedicine; Scientific consultancy in the fields of genetics, genomics and biomedicine; Technological consultation services in the fields of genetics, genomics and biomedicine; Design services in the fields of genetics, genomics and biomedicine; Design consultation in the fields of genetics, genomics and biomedicine; IT consultancy, advisory and information services in the fields of genetics, genomics and biomedicine; Provision of scientific information and scientific data relating to genetics, genomics and biomedicine. Medical services in the fields of genetics, genomics and biomedicine; Veterinary services in the fields of genetics, genomics and biomedicine; Provision of medical information and medical data relating to genetics, genomics and biomedicine.

Abrégé

The present invention relates to improved adeno-associated virus (AAV) particles for gene delivery and gene therapy. Provided are adeno associated virus (AAV) particles that comprise a modified capsid. The present invention further relates to methods for producing the improved AAV particles of this invention by removing natural binding sites in adeno associated virus (AAV) capsids and introducing ligand binding sites into said capsid to provide AAVs that transduce only particular cells of interest. An additional aspect of the present invention relates to modified AAV particles for use in the treatment of a disease and methods for treating a disease, comprising administering the modified AAV particles to a subject in need thereof. Yet a further aspect of this invention relates to the AAV particles of this invention for the transfection of cells, for example as a gene delivery tool in basic research.

Classes IPC  ?

• C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• C12N 15/86 - Vecteurs viraux

Abrégé

The present invention relates to improved adeno-associated virus (AAV) particles for gene delivery and gene therapy. Provided are adeno associated virus (AAV) particles that comprise a modified capsid. The present invention further relates to methods for producing the improved AAV particles of this invention by removing natural binding sites in adeno associated virus (AAV) capsids and introducing ligand binding sites into said capsid to provide AAVs that transduce only particular cells of interest. An additional aspect of the present invention relates to modified AAV particles for use in the treatment of a disease and methods for treating a disease, comprising administering the modified AAV particles to a subject in need thereof. Yet a further aspect of this invention relates to the AAV particles of this invention for the transfection of cells, for example as a gene delivery tool in basic research.

Classes IPC  ?

• C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
• C12N 15/86 - Vecteurs viraux
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique

Produits et services

Information technology and audio-visual, multimedia and photographic devices. Scientific and technological services. Medical services; Veterinary services; Human hygiene and beauty care; Hygienic and beauty care for animals; Agriculture, aquaculture, horticulture and forestry services.

Abrégé

The present invention relates to novel transposon constructs and uses thereof. The novel transposon constructs of this invention have been developed based on structure-guided engineering approaches of the IS608 transposon. Provided are polynucleotides encoding for transposon ends, which may advantageously be used for site-specific insertion of a nucleotide sequence of interest into the genome of a target cell or a target DNA molecule. The invention provides further nucleic acids, vectors and recombinant cells encoding or containing the improved polynucleotides encoding for transposon ends, as well as a transposase system. Hence, the invention provides many tools for molecular genetic approaches for genome alteration, such as cloning strategies. Furthermore provided are medical and non-medical uses of the polynucleotides of the invention. The invention is in particular useful as a tool for gene delivery in genetically modified cell based therapeutic approaches for treating various diseases and for genetic tagging of endogenous proteins in research.

Classes IPC  ?

• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 9/22 - Ribonucléases
• C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome

Abrégé

[1] The present invention provides a method for detecting structural variations (SV) within genomes of single cells or population of single cells by integrating a three-layered information of sequencing read depth, read strand orientation and haplotype phase. The method of the invention can detect deletions, duplications, polyploidies, translocations, inversions, and copy number neutral loss of heterozygosity (CNN-LOH), and more. The method of the invention can fully karyotype a genome comprehensively, and may be applied in research and clinical approaches. For example, the methods of the invention are useful for analysing cellular samples of patients for diagnosing or aiding a diagnosis, in reproductive medicine to detect embryonic abnormalities, or during therapeutic approaches based on cellular therapies to quality control genetically engineered cells, such as in adoptive T cell therapy and others. The method of the invention may further be applied in research to decipher the karyotypes of cellular models (cell lines), patient samples, or to further unravel genetic and mechanistic pathways leading to the generation of any SV within genomes.

Classes IPC  ?

• G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
• G16B 30/10 - Alignement de séquence; Recherche d’homologie
• G16B 50/10 - Ontologies; Annotations

Abrégé

An engineered adenovirus penton base protomer, wherein the penton base protomer comprises a first RGD-loop, a second RGD-loop, a variable loop (V loop), an Adenovirus fiber protein binding cleft, and an N-terminal domain; wherein at least one of the first RGD-loop, the second RGD-loop, and the V loop comprises at least one inserted non-adenoviral antigenic polypeptide; and wherein the engineered adenovirus penton base protomer is capable of assembling into virus-like particles (VLPs).

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
• A61K 39/12 - Antigènes viraux
• C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification